Caspofungin for the treatment of candidaemia in patients with haematological malignancies

Clinical Microbiology and Infection

Volumn 16, Issue 3, 2010, Pages 298-301

  Pagano, L ^a   Fianchi, L ^a   Fanci, R ^b   Candoni, A ^c   Caira, M ^a   Posteraro, B ^a   Morselli, M ^d   Valentini, C G ^a   Farina, G ^e   Mitra, M E ^f   Offidani, M ^g   Sanguinetti, M ^a   Tosti, M E ^h   Nosari, A ⁱ   Leone, G ^a   Viale, P ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h ISTITUTO SUPERIORE DI SANITÀ   (Italy)

ⁱ Niguarda Ca' Grande Hospital   (Italy)

Author keywords

Candidaemia; Caspofungin; Leukaemia

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANDIDEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; LOADING DRUG DOSE; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 76749143789     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02832.x     Document Type: Article

References (13)

1. Pagano L, Caira M, Candoni A. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
2. Walsh TS, De Pauw B, Anaissie E, Martino P. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. J Med Vet Mycol 1994, 32:33-51.
3. Ribeiro P, Sousa AB, Nunes O. Candidemia in acute leukaemia patients. Support Care Cancer 1997, 5:249-251.
4. Mora-Duarte J, Betts R, Rotstein C. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
5. Pappas PG, Rotstein CM, Betts RF. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
6. Reboli AC, Rotstein C, Pappas PG. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
7. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003, 22:651-655.
8. Arrieta A, Queiroz-Telles F, Berezin E. Micafungin versus liposomal amphotericin B (AmBisome®) in paediatric patients with invasive candidiasis or candidemia. Clinical Microbiology and Infection. 17th ECCMID 31 March-3 April 2007 Munich, Abst 1732_85
9. Kuse ER, Chetchotisakd P, da Cunha CA. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
10. Segal BH, Herbrecht R, Stevens DA. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis 2008, 47:674-683.
11. Pappas PG, Kauffman CA, Andes D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
12. Betts R, Glasmacher A, Maertens J. Efficacy of caspofungin against invasive candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006, 106:466-473.
13. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard 2002, 2nd edn, NCCLS document M27-A2, Wayne, PA, National Committee for Clinical Laboratory Standards